Bispecific Antibody Development for Brain Tumors

Bispecific antibodies (BsAb) are artificial antibodies that can bind two different specific antigens at the same time, bridging the gap between target cells and functional molecules (cells) and stimulating a directed immune response. BsAb does not exist in its natural state and can only be prepared artificially. The study of BsAb is of great importance for immunotherapy of brain tumors.

We provide services for the development of BsAb for brain tumors

BsAb comes in various forms and has two different sites that can target different antigens. This bi-specificity of BsAb means that one antigen-binding site can be used to bind to the target cell while the other antigen-binding site can be used to recruit other cells or molecules. Alfa Cytology utilizes a unique immune cell bridger platform that allows us to rapidly develop BsAb molecules that are redirected by immune cells to the brain tumor microenvironment. In addition, we can provide you with fast and efficient BsAb expression services using our optimized and proven mammalian cell expression platform.

BsAb development services

Our technology platform specifically identifies both tumor-associated antigens on brain tumor cells and CD3 molecules or other co-stimulatory molecules on immune cells (e.g., T cells or NK cells). The immune cells and tumor cells are then drawn together, thus efficiently and selectively activating immune cells in the brain tumor microenvironment and preventing non-specific activation of peripheral immune cells. In addition, the platform we have built has very good flexibility to design molecules with different structures and binding modes to achieve those molecular mechanisms of action that cannot be achieved by relying on combination therapies.

Advantages of the BsAb development services we offer

• No sequence mutations and low engineering.
• Efficient development process and comparable druggability to monoclonal antibodies.
• Possibility to enhance ADCC/CDC effects by Fc engineering.
• No additional purification process and no in vitro assembly is required.

BsAb expression services

With our extensive experience in brain tumor antibody drug development, we can provide high-quality BsAb expression services to support the brain tumor drug discovery research process for a variety of applications, including high-throughput screening, in vitro activity and functional assays, and in vivo animal studies. We use improved mammalian transient expression technology and continuous optimization of expression protocols and media to improve antibody yields, fully guaranteeing successful delivery of BsAb expression projects.

General service flow

Advantages of the BsAb expression services we offer

• Self-optimized platform with better glycosylation and post-translational modifications.
• With various purification technologies such as protein A/G/L affinity purification, anion and cation exchange chromatography, and molecular sieves.
• With powerful quality control analysis capabilities for SEC-HPLC, activity assay, and endotoxin level determination.

BsAb opens up a whole new field in brain tumor therapy. With our unique platform, Alfa Cytology can develop BsAb against brain tumors to effectively enhance the binding specificity and targeting of antibodies to brain tumor cells and reduce side effects such as off-targeting. Please feel free to contact us for customized BsAb development and expression services for brain tumors.